Last reviewed · How we verify
Intramuscular naloxone
At a glance
| Generic name | Intramuscular naloxone |
|---|---|
| Also known as | Naloxone B Braun 0,4 mg/ml |
| Sponsor | Norwegian University of Science and Technology |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Weight loss
- Headache
- Anxiety
- Tiredness
- Cough
- Loss of appetite
- Nausea
- Puffiness or swelling of eyelids or eyes
- Sweating
- Blurred or double vision
- General dizziness
- Dizziness, faintness, lightheadedness upon rising
Key clinical trials
- Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses (PHASE4)
- iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers (PHASE1)
- Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol (PHASE1)
- Proof of Concept (PoC) Evaluation of Naloxone Unique Intramuscular (IM) Injection (PHASE1)
- Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia (PHASE1)
- Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg (PHASE1)
- Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults (PHASE4)
- Naltrexone for Overdose Prevention (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intramuscular naloxone CI brief — competitive landscape report
- Intramuscular naloxone updates RSS · CI watch RSS
- Norwegian University of Science and Technology portfolio CI